Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nasus Pharma (NYSE: NSRX) announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer effective Nov 20, 2025. Rubin brings more than two decades of financial leadership in biotechnology and pharma and will lead corporate finance, financial planning, capital strategy, and investor relations as Nasus advances its intranasal therapeutic pipeline toward clinical and commercial milestones.
Rubin previously served as CFO at Protalix BioTherapeutics and BrainStorm Cell Therapeutics and held treasury leadership at Teva. He holds a BA in Business Management and an MBA in Accounting and Finance, both summa cum laude. Company leaders said Rubin’s capital markets experience will support Nasus’s growth phase.
Nasus Pharma (NYSE: NSRX) ha annunciato la nomina di Eyal Rubin come Vicepresidente Esecutivo e Chief Financial Officer, con effetto dal 20 novembre 2025. Rubin porta oltre due decadi di leadership finanziaria nel biotech e nel settore farmaceutico e guiderà la finanza aziendale, la pianificazione finanziaria, la strategia di capitale e le relazioni con gli investitori mentre Nasus avanza con il suo portafoglio terapeutico intranasale verso traguardi clinici e commerciali.
In precedenza Rubin è stato CFO di Protalix BioTherapeutics e BrainStorm Cell Therapeutics e ha ricoperto ruoli di tesoreria in Teva. Possiede una laurea in Gestione Aziendale e un MBA in contabilità e finanza, entrambi con lode summa. I vertici dell'azienda hanno detto che l'esperienza di Rubin nei mercati dei capitali sosterrà la fase di crescita di Nasus.
Nasus Pharma (NYSE: NSRX) anunció el nombramiento de Eyal Rubin como Vicepresidente Ejecutivo y Director Financiero, con efecto a partir del 20 de noviembre de 2025. Rubin aporta más de dos décadas de liderazgo financiero en biotecnología y farmacéutica y dirigirá finanzas corporativas, planificación financiera, estrategia de capital y relaciones con los inversores a medida que Nasus avanza con su cartera terapéutica intranasal hacia hitos clínicos y comerciales.
Rubin se desempeñó previamente como CFO en Protalix BioTherapeutics y BrainStorm Cell Therapeutics y ocupó posiciones de liderazgo de tesorería en Teva. Posee una licenciatura en Administración de Empresas y un MBA en Contabilidad y Finanzas, ambos con summa cum laude. Los líderes de la empresa dijeron que la experiencia de Rubin en mercados de capitales apoyará la etapa de crecimiento de Nasus.
Nasus Pharma (NYSE: NSRX) 는 Eyal Rubin 을 최고재무책임자(CFO) 겸 부사장으로 2025년 11월 20일부로 임명했다고 발표했습니다. Rubin 은 생명공학 및 제약 분야에서 20년이 넘는 재무 리더십을 갖고 있으며 Nasus 의 기업 재무, 재무 기획, 자본 전략 및 투자자 관계를 주도하여 Intranasal 치료 파이프라인이 임상 및 상업적 이정표에 도달하도록 할 것입니다.
Rubin 은 이전에 Protalix BioTherapeutics 와 BrainStorm Cell Therapeutics 의 CFO 로 재직했으며 Teva 에서 자금 운용 리더십을 맡았습니다. 그는 경영학 학사와 회계 및 재무를 전공한 MBA 를 모두 만점으로 졸업했습니다. 회사의 경영진은 Rubin 의 자본시장을 통한 경험이 Nasus 의 성장 단계에 도움이 될 것이라고 밝혔습니다.
Nasus Pharma (NYSE: NSRX) a annoncé la nomination de Eyal Rubin au poste de Vice-président exécutif et Directeur financier, à compter du 20 novembre 2025. Rubin apporte plus de deux décennies de leadership financier dans les biotechnologies et les secteurs pharmaceutiques et dirigera les finances d'entreprise, la planification financière, la stratégie de capital et les relations avec les investisseurs pendant que Nasus fait progresser son portefeuille thérapeutique intranasal vers des jalons cliniques et commerciaux.
Rubin a précédemment été CFO chez Protalix BioTherapeutics et BrainStorm Cell Therapeutics et a occupé des postes de direction de trésorerie chez Teva. Il est titulaire d'une licence en gestion des affaires et d'un MBA en comptabilité et finances, tous deux summa cum laude. Les dirigeants de la société ont déclaré que l'expérience de Rubin sur les marchés de capital soutiendra la phase de croissance de Nasus.
Nasus Pharma (NYSE: NSRX) gab die Berufung von Eyal Rubin zum Executive Vice President und Chief Financial Officer bekannt, wirksam ab dem 20. November 2025. Rubin bringt mehr als zwei Jahrzehnte Führungsqualitäten im Finanzbereich in Biotechnologie und Pharma mit und wird die Bereiche Unternehmensfinanzen, Finanzplanung, Kapitalstrategie und Investor Relations leiten, während Nasus seine intranasale Therapeutika-Pipeline auf klinische und kommerzielle Meilensteine vorantreibt.
Rubin war zuvor CFO bei Protalix BioTherapeutics und BrainStorm Cell Therapeutics und hatte Führungspositionen im Bereich Treasury bei Teva. Er besitzt einen BA in Betriebswirtschaft und einen MBA in Rechnungswesen und Finanzen, beide mit summa cum laude. Die Unternehmensführung sagte, Rubins Kapitalmarkterfahrung werde Nasus’ Wachstumsphase unterstützen.
ناسوس فارما (بورصة نيويورك: NSRX) أعلنت تعيين إيال روبين كنائب رئيس تنفيذي ورئيس قسم الشؤون المالية، اعتباراً من 20 نوفمبر 2025. يجلب روبين أكثر من عقدين من القيادة المالية في علوم الأحياء الحيوية والأدوية وسيقود التمويل المؤسسي، والتخطيط المالي، واستراتيجية رأس المال، علاقات المستثمرين بينما تتقدم Nasus بمحفظتها العلاجية الأنفية داخل الأنف نحو معالم سريرية وتجارية.
شغل روبين سابقاً منصب المدير المالي في Protalix BioTherapeutics وBrainStorm Cell Therapeutics وتولى قيادة الخزينة في Teva. يحمل درجة البكالوريوس في إدارة الأعمال ودرجة ماجستير في إدارة الأعمال في المحاسبة والمالية، كلاهما بتقدير امتياز. قال قادة الشركة إن خبرة روبين في أسواق رأس المال ستدعم مرحلة النمو لشركة Nasus.
- Appointment of experienced CFO with 20+ years in biotech and pharma
- Leadership scope includes corporate finance, capital strategy, and investor relations
- Relevant prior CFO roles at Protalix and BrainStorm, plus treasury role at Teva
- None.
Veteran CFO appointment underscores the Company’s commitment to building a strong leadership team as it advances its clinical and commercial strategy
TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma’s executive leadership team.
Mr. Rubin will lead and oversee Nasus Pharma’s financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the Company advances its pipeline of intranasal therapeutics towards achieving key clinical and commercial milestones.
“We are delighted to welcome Eyal to our leadership team,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “We believe his deep financial expertise, strong command of capital markets, and successful track record of supporting clinical-stage and commercial-stage biotech companies make him the ideal addition to our leadership team as we enter an important phase of growth.”
“We’re pleased to have Eyal join Nasus Pharma,” said Udi Gilboa, Executive Chairman of Nasus Pharma. “His extensive experience in both emerging biotechnology companies and commercial-stage pharmaceutical organizations will prove highly valuable to Nasus as we continue to strengthen our financial and operational capabilities. We are confident that his financial leadership will bolster the Company as our clinical programs progress.”
Mr. Rubin previously served as Chief Financial Officer and Senior Vice President of Protalix BioTherapeutics, Inc. where he led financial operations, strategy, and capital markets activities. Prior to that, Mr. Rubin served as Chief Financial Officer of BrainStorm Cell Therapeutics, Inc. and at Teva Pharmaceutical Industries Ltd.as Vice President and Head of Corporate Treasury. Mr. Rubin holds a BA in Business Management from the College of Management Academic Studies, Israel, and an MBA in Accounting and Finance from Bar-Ilan University, both summa cum laude.
“I am excited to join Nasus Pharma at such a pivotal moment,” said Mr. Rubin. “I believe the Company’s innovative intranasal drug delivery platform and advancing clinical program represent a significant opportunity to bring innovative drug delivery products to patients and address significant unmet medical needs. I look forward to partnering with the leadership team to support the Company’s continued progress and long-term growth.”
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or Linkedin.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding: the Company’s expectations regarding its growth, the advancement of its clinical programs, and anticipated clinical and commercial milestones; the Company’s plans to strengthen its financial and operational capabilities and build its leadership team; that Mr. Rubin’s experience will prove highly valuable to the Company; the significant opportunity of the Company’s intranasal drug delivery platform and its ability to bring innovative drug delivery products to patients and address significant unmet medical needs; and the Company’s beliefs about the impact of its leadership additions, including the appointment of Mr. Rubin, on its long-term growth and execution of its corporate strategy. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com
Investor Contact
Arx Investor Relations
North American Equities Desk
nasus@arxhq.com
FAQ
Who is the new CFO of Nasus Pharma (NSRX) and when was he appointed?
What responsibilities will Eyal Rubin have at Nasus Pharma (NSRX)?
What prior experience does Nasus Pharma’s new CFO have that matters to NSRX investors?
How might the NSRX CFO appointment affect Nasus Pharma’s capital strategy?
Where can investors find more information about Nasus Pharma leadership changes for NSRX?
